Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: The FARO-2 study

Daniela Paola Roggeri, Mario Cozzolino, Sandro Mazzaferro, Diego Brancaccio, Ernesto Paoletti, Alessandro Roggeri, Anna Maria Costanzo, Umberto di Luzio Paparatti, Vincenzo Festa, Piergiorgio Messa

Research output: Contribution to journalArticlepeer-review


Results: Two prominent treatment groups were identified, ie, one on oral calcitriol (n=105) and the other on intravenous paricalcitol (n=33); the intravenous calcitriol and intravenous paricalcitol + cinacalcet combination groups were not analyzed due to low patient numbers. At baseline, serum PTH levels were significantly higher in the intravenous paricalcitol group (P

Conclusion: Intravenous paricalcitol significantly increased the percentage of patients at target for the combined endpoint of PTH, calcium, and phosphate (P=0.001). The total cost of treatment for the patients treated with intravenous paricalcitol 6 months after entry to dialysis was not significantly higher than the cost for patients treated with oral calcitriol.

Background: The aim of this analysis was to estimate biochemical parameters and the costs of treatment of secondary hyperparathyroidism (SHPT) in a subpopulation of the FARO-2 study.

Methods: The FARO-2 observational study aimed at evaluating the patterns of treatment for SHPT in naïve hemodialysis patients. Data related to pharmacological treatments and biochemical parameters (parathyroid hormone [PTH], calcium, phosphate) were recorded at entry to hemodialysis (baseline) and 6 months later (second survey). The analysis was performed from the Italian National Health Service perspective.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalInternational Journal of Nephrology and Renovascular Disease
Publication statusPublished - Dec 16 2014


  • Cost consequences analysis
  • Outcomes
  • Secondary hyperparathyroidism
  • SHPT treatments
  • Therapeutic costs

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: The FARO-2 study'. Together they form a unique fingerprint.

Cite this